There is now proof that the perceived risk of cancer from radiation during exposure to cardiac CT may be exaggerated.
Radiology and cardiovascular researchers from the Medical University of South Carolina in Charleston, S.C., also said that the new estimates are several times lower than previously published conclusions.
Cardiac CT Does Justice to Evaluation of Coronary Artery Stenosis
An extensive study carried out by Dutch researchers showed that cardiac CT can effectively evaluate coronary artery stenosis.
Advertisement
In earlier studies, many scientists claimed that the risk of cancer from radiation exposure during CT for cardiovascular disease was approximately 1 in 114, but the new study suggests that the risk is 1 in 1000.
U. Joseph Schoepf, MD, and colleagues from MUSC, have said that previous studies assessing lifetime risks of cancer from radiation in cardiac CT are based on unreliable models of patients who undergo CT for cardiovascular disease.
![Ultra-Violet Radiation]( "Ultra-Violet Radiation")
Ultraviolet radiations are electromagnetic radiations with wavelengths shorter than the shortest wavelength of visible light, " the rays beyond the rainbow".
For the study, the researchers examined 104 consecutive patients undergoing 64-slice cardiac CT at the Medical University of South Carolina. The majority of the patients were male with median age of 59 and median weight of 202 pounds.
The team converted organ radiation doses into risk using a previously published and validated measure. Patient cancer risks were adjusted taking into account patient sex, age and weight, the latter being an often neglected factor influencing radiation risk.
Scheopf said that the new risk in this patient population, which mirrors more closely the typical patients who receive cardiac CT, was 1 in 1000.
"Thus, in a real-life clinical patient group, the realistic risk of radiation induced cancer from cardiac CT is substantially lower than previously reported for general populations," said Scheopf.
He added that radiation exposure is a serious issue and patients need to talk to their doctors before undergoing any tests that exposes them to radiation to ensure the test is appropriate and the patient fits under patient selection guidelines published by the American Heart Association and the American College of Radiology.
The findings of the study were presented at the annual meeting of the Radiological Society of North America in Chicago.
Source: ANI
SAV/SK
Ultra-Violet Radiation
Ultraviolet radiations are electromagnetic radiations with wavelengths shorter than the shortest wavelength of visible light, " the rays beyond the rainbow".
Advertisement
For the study, the researchers examined 104 consecutive patients undergoing 64-slice cardiac CT at the Medical University of South Carolina. The majority of the patients were male with median age of 59 and median weight of 202 pounds.
The team converted organ radiation doses into risk using a previously published and validated measure. Patient cancer risks were adjusted taking into account patient sex, age and weight, the latter being an often neglected factor influencing radiation risk.
Scheopf said that the new risk in this patient population, which mirrors more closely the typical patients who receive cardiac CT, was 1 in 1000.
"Thus, in a real-life clinical patient group, the realistic risk of radiation induced cancer from cardiac CT is substantially lower than previously reported for general populations," said Scheopf.
He added that radiation exposure is a serious issue and patients need to talk to their doctors before undergoing any tests that exposes them to radiation to ensure the test is appropriate and the patient fits under patient selection guidelines published by the American Heart Association and the American College of Radiology.
The findings of the study were presented at the annual meeting of the Radiological Society of North America in Chicago.
Source: ANI
SAV/SK
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable